

# Annalisa Tassone

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2223679/publications.pdf>

Version: 2024-02-01

29  
papers

1,383  
citations

430874

18  
h-index

477307

29  
g-index

29  
all docs

29  
docs citations

29  
times ranked

1158  
citing authors

#	ARTICLE	IF	CITATIONS
1	Impairment of bidirectional synaptic plasticity in the striatum of a mouse model of DYT1 dystonia: role of endogenous acetylcholine. <i>Brain</i> , 2009, 132, 2336-2349.	7.6	197
2	Anticholinergic drugs rescue synaptic plasticity in DYT1 dystonia: Role of M <sub>1</sub> muscarinic receptors. <i>Movement Disorders</i> , 2014, 29, 1655-1665.	3.9	152
3	Cholinergic Dysfunction Alters Synaptic Integration between Thalamostriatal and Corticostriatal Inputs in DYT1 Dystonia. <i>Journal of Neuroscience</i> , 2012, 32, 11991-12004.	3.6	93
4	Dopamine D2 receptor dysfunction is rescued by adenosine A2A receptor antagonism in a model of DYT1 dystonia. <i>Neurobiology of Disease</i> , 2010, 38, 434-445.	4.4	92
5	Impaired striatal D2 receptor function leads to enhanced GABA transmission in a mouse model of DYT1 dystonia. <i>Neurobiology of Disease</i> , 2009, 34, 133-145.	4.4	80
6	Developmental Profile of the Aberrant Dopamine D2 Receptor Response in Striatal Cholinergic Interneurons in DYT1 Dystonia. <i>PLoS ONE</i> , 2011, 6, e24261.	2.5	77
7	Cholinergic dysregulation produced by selective inactivation of the dystonia-associated protein torsinA. <i>Neurobiology of Disease</i> , 2012, 47, 416-427.	4.4	71
8	Regional specificity of synaptic plasticity deficits in a knock-in mouse model of DYT1 dystonia. <i>Neurobiology of Disease</i> , 2014, 65, 124-132.	4.4	69
9	Early structural and functional plasticity alterations in a susceptibility period of DYT1 dystonia mouse striatum. <i>ELife</i> , 2018, 7, .	6.0	60
10	Homeostatic changes of the endocannabinoid system in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 216-222.	3.9	45
11	<sc>RGS</sc> 9 rescues dopamine D2 receptor levels and signaling in <i><sc>DYT</sc> 1</i> dystonia mouse models. <i>EMBO Molecular Medicine</i> , 2019, 11, .	6.9	44
12	Powerful inhibitory action of mu opioid receptors (MOR) on cholinergic interneuron excitability in the dorsal striatum. <i>Neuropharmacology</i> , 2013, 75, 78-85.	4.1	43
13	Enhanced sensitivity to group II mGlu receptor activation at corticostriatal synapses in mice lacking the familial parkinsonism-linked genes PINK1 or Parkin. <i>Experimental Neurology</i> , 2009, 215, 388-396.	4.1	37
14	Activation of 5-HT6 receptors inhibits corticostriatal glutamatergic transmission. <i>Neuropharmacology</i> , 2011, 61, 632-637.	4.1	36
15	Abnormal striatal plasticity in a DYT11/SCGE myoclonus dystonia mouse model is reversed by adenosine A2A receptor inhibition. <i>Neurobiology of Disease</i> , 2017, 108, 128-139.	4.4	34
16	Negative allosteric modulation of mGlu5 receptor rescues striatal D2 dopamine receptor dysfunction in rodent models of DYT1 dystonia. <i>Neuropharmacology</i> , 2014, 85, 440-450.	4.1	33
17	Distinct roles of group I mGlu receptors in striatal function. <i>Neuropharmacology</i> , 2008, 55, 392-395.	4.1	32
18	Torsin A Localization in the Mouse Cerebellar Synaptic Circuitry. <i>PLoS ONE</i> , 2013, 8, e68063.	2.5	24

#	ARTICLE	IF	CITATIONS
19	Impaired dopamine- and adenosine-mediated signaling and plasticity in a novel rodent model for DYT25 dystonia. <i>Neurobiology of Disease</i> , 2020, 134, 104634.	4.4	22
20	Enhanced mu opioid receptorâ€“dependent opioidergic modulation of striatal cholinergic transmission in DYT1 dystonia. <i>Movement Disorders</i> , 2018, 33, 310-320.	3.9	20
21	Loss of Non-Apoptotic Role of Caspase-3 in the PINK1 Mouse Model of Parkinsonâ€™s Disease. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3407.	4.1	18
22	Age-related functional changes of high-voltage-activated calcium channels in different neuronal subtypes of mouse striatum. <i>Neuroscience</i> , 2008, 152, 469-476.	2.3	17
23	Optogenetic Activation of Striatopallidal Neurons Reveals Altered HCN Gating in DYT1 Dystonia. <i>Cell Reports</i> , 2020, 31, 107644.	6.4	16
24	Altered profile and D2-dopamine receptor modulation of high voltage-activated calcium current in striatal medium spiny neurons from animal models of Parkinson's disease. <i>Neuroscience</i> , 2011, 177, 240-251.	2.3	15
25	Experimental Models of Dystonia. <i>International Review of Neurobiology</i> , 2011, 98, 551-572.	2.0	15
26	Seletracetam (ucb 44212) inhibits highâ€“voltageâ€“activated Ca <sup>2+</sup> currents and intracellular Ca <sup>2+</sup> increase in rat cortical neurons in vitro. <i>Epilepsia</i> , 2009, 50, 702-710.	5.1	14
27	Electrophysiology of 5-HT6 Receptors. <i>International Review of Neurobiology</i> , 2010, 94, 111-128.	2.0	10
28	Vesicular Acetylcholine Transporter Alters Cholinergic Tone and Synaptic Plasticity in <sc>DYT1</sc> Dystonia. <i>Movement Disorders</i> , 2021, 36, 2768-2779.	3.9	10
29	Alphaâ€“Synuclein is Involved in <sc>DYT1</sc> Dystonia Striatal Synaptic Dysfunction. <i>Movement Disorders</i> , 2022, 37, 949-961.	3.9	7